Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Butler, Christopher; Dorward, Jienchi; Yu, Ly‐Mee; Gbinigie, Oghenekome; Hayward, Gail; R. Saville, Benjamin; van Hecke, Oliver; Berry, Nick; A. Detry, Michelle; Saunders, Christina; Fitzgerald, Mark; Harris, Victoria; Patel, Mihir; de Lusignan, Simon; Ogburn, Emma; Evans, Philip; Thomas, Nicholas; Hobbs, Richard

doi:10.1016/s0140-6736(21)00461-x

Public

Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial

Published in The Lancet • Mar 1, 2021

Authors:

Christopher Butler

Jienchi Dorward

Ly‐Mee Yu

Abstract

BACKGROUND: Azithromycin, an antibiotic with potential antiviral and anti-inflammatory properties, has been used to treat COVID-19, but evidence from community randomised trials is lacking. We aimed to assess the effectiveness of azithromycin to treat suspected COVID-19 among people in the community...

Subject

Azithromycin

Medicine

Randomized controlled trial

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!